Original Article

You have full text access to this OnlineOpen article

Combined-modality treatment for isolated recurrences of breast carcinoma

Update on 30 years of experience at the University of Texas M. D. Anderson Cancer Center and assessment of prognostic factors

  1. Emer O. Hanrahan M.D.1,
  2. Kristine R. Broglio M.S.2,
  3. Aman U. Buzdar M.D.1,
  4. Richard L. Theriault D.O.1,
  5. Vicente Valero M.D.1,
  6. Massimo Cristofanilli M.D.1,
  7. Guosheng Yin Ph.D.2,
  8. Shu-Wan C. Kau R.N.1,
  9. Gabriel N. Hortobagyi M.D.1,
  10. Edgardo Rivera M.D.1,†,*

Article first published online: 26 JUL 2005

DOI: 10.1002/cncr.21305

Issue

Cancer

Cancer

Volume 104, Issue 6, pages 1158–1171, 15 September 2005

Additional Information

How to Cite

Hanrahan, E. O., Broglio, K. R., Buzdar, A. U., Theriault, R. L., Valero, V., Cristofanilli, M., Yin, G., Kau, S.-W. C., Hortobagyi, G. N. and Rivera, E. (2005), Combined-modality treatment for isolated recurrences of breast carcinoma. Cancer, 104: 1158–1171. doi: 10.1002/cncr.21305

Author Information

  1. 1

    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 794-4200

*Department of Breast Medical Oncology, Unit 1354, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 301439, Houston, TX 77230-1439

Publication History

  1. Issue published online: 31 AUG 2005
  2. Article first published online: 26 JUL 2005
  3. Manuscript Accepted: 23 MAY 2005
  4. Manuscript Revised: 25 APR 2005
  5. Manuscript Received: 18 APR 2005

Funded by

  • Aventis Pharmaceuticals

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (196K)

REFERENCES

  • 1
    Buzdar AU, Blumenschein GR, Montague ED, et al. Combined modality approach in breast cancer with isolated multiple metastases. Am J Clin Oncol. 1984; 6: 45–50.
  • 2
    Donegan WL, Perez-Mesa LM, Watson FR. A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet. 1966; 122: 529–540.
  • 3
    Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy: analysis of 716 consecutive patients. Cancer. 1978; 41: 1170–1178.
    Direct Link:
  • 4
    Di Petro S, Bertario L, Piva L. Prognosis and treatment of locoregional breast cancer recurrences: critical consideration on 120 cases. Tumori. 1980; 66: 331–338.
  • 5
    Gilliland MD, Barton RM, Copeland EM III. The implications of local recurrence of breast cancer as the first site of therapeutic failure. Ann Surg. 1983; 197: 284–287.
  • 6
    Toonkel LM, Fix I, Jacobsen LH, et al. The significance of local recurrence of carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1983; 9: 33–39.
  • 7
    Bedwinek JM, Fineberg B, Lee J, et al. Analysis of failures following local treatment of isolated local-regional recurrence of breast cancer. Int J Radiat Oncol Biol Phys. 1981; 7: 581–585.
  • 8
    Fentiman IS, La Velle MA, Caplan D, et al. The significance of supraclcavicular fossa node recurrence after mastectomy. Cancer. 1986; 57: 908–910.
    Direct Link:
  • 9
    Beck TM, Hart NE, Woodward DA, et al. Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. J Clin Oncol. 1983; 1: 400–405.
  • 10
    Holmes FA, Buzdar AU, Kau S-W, et al. Combined modality approach for patients with isolated recurrences of breast cancer (IV-NED): the M. D. Anderson Cancer Center experience. Breast Dis. 1994; 7: 7–20.
  • 11
    Rivera E, Holmes FA, Buzdar AU, et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with Stage IV breast cancer with no evidence of disease. Breast J. 2002; 8: 2–9.
    Direct Link:
  • 12
    Buzdar AU, Blumenschein GR, Smith T, et al. Adjuvant chemotherapy following regional therapy for isolated recurrences of breast cancer (Stage IV-NED). J Surg Oncol. 1979; 12: 27–40.
    Direct Link:
  • 13
    Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999; 17: 2341–2354.
  • 14
    Nabholtz JM, Falkson G, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, Phase III trial. J Clin Oncol. 2003; 21: 968–975.
  • 15
    Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999; 17: 2355–2364.
  • 16
    Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999; 17: 1413–1424.
  • 17
    Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized Phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer. 1999; 35: 1194–1201.
  • 18
    National Cancer Institute. Common Toxicity Criteria of the National Cancer Institute, version 2.0. Available at URL: http://ctep.info.nih.gov/reporting/CTC-3.html [accessed February 7, 2005].
  • 19
    Smith TJ, Davidson NE, Schapira DV, et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol. 1999; 17: 1080–1082.
  • 20
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457–481, 562–563.
  • 21
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187–220.
  • 22
    GreeneFL, PageDL, FlemingID, et al., editors. AJCC cancer staging handbook. TNM classification of malignant tumors, 6th ed. New York: John Wiley & Sons, 2002.
  • 23
    Baral E, Ogenstad S, Wallgren A. The effect of adjuvant radiotherapy on the time of occurrence and prognosis of local recurrence in primary operable breast cancer. Cancer. 1985; 56: 2779–2782.
    Direct Link:
  • 24
    Chen KK-Y, Montague ED, Oswald MJ. Results of irradiation in the treatment of locoregional breast cancer recurrence. Cancer. 1985; 56: 1269–1273.
    Direct Link:
  • 25
    Janjan NA, McNeese MD, Buzdar AU, et al: Management of locoregional recurrent breast cancer. Cancer. 1986; 58: 1552–1556.
    Direct Link:
  • 26
    Borner M, Bacchi M, Goldhirsch A, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a Phase III multicentre study comparing systemic treatment with observation after excision and radiation. J Clin Oncol. 1994; 12: 2071–2077.
  • 27
    Waeber M, Castiglione-Gertsch M, Dietrich D, et al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a Phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol. 2003; 14: 1215–1221.
  • 28
    Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for Stage IV oligometastatic breast cancer. J Clin Oncol. 2002; 20: 707–718.
  • 29
    Bonneterre J, Roche H, Monnier A, et al. Docetaxel versus 5-fluorouracil plus vinorlebine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer. 2002; 87: 1210–1215.
  • 30
    Roche H, Fumoleau P, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 versus 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer [abstract]. Breast Cancer Res Treat. 2004; 88(Suppl 1): S16–S17.
  • 31
    Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Eng J Med. 2005; 352: 2302–2313.
  • 32
    The ATAC Trialists' Group. Anastrozole alone or combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC trial. Lancet. 2002; 359: 2131–2139.
  • 33
    Howell A, on behalf of the ATAC Trialists' Group. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer—updated efficacy results based on a median follow-up of 5 years [abstract]. Breast Cancer Res Treat. 2004; 88(Suppl 1): S7.
  • 34
    Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen for early stage breast cancer. N Engl J Med. 2003; 349: 1793–1802.
  • 35
    Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 1081–1092.
  • 36
    Lionetto R, Pronzato P, Bertelli GF, et al. Survival of patients with relapsing breast cancer: analysis of 302 patients. Oncology. 1986; 43: 278–282.
  • 37
    Clark GM, Sledge GW Jr., Osborne CK, et al. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol. 1987; 5: 55–61.
  • 38
    Shek LLM, Godolphin W. Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res. 1988; 48: 5565–5569.
  • 39
    Brunner KW, Harder F, Greiner R, et al. Local relapse after surgery for breast cancer: prognostic factors and therapeutic implications. Schweiz Med Wochenschr. 1988; 118: 52–1981.
  • 40
    Koenders PG, Beex LV, Kloppenborg PW, et al. Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast Cancer Res Treat. 1992; 21: 173–180.
  • 41
    Kamby C, Sengelov L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat. 1997; 45: 181–192.
  • 42
    Insa A, Lluch A, Prosper F, et al. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat. 1999; 56: 67–78.
  • 43
    Jatoi I, Hilsenbeck SG, Clark GM, et al. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999; 17: 2334–2340.
  • 44
    Juan O, Lluch A, de Paz L, et al. Prognostic factors in patients with isolated recurrences of breast cancer (Stage IV-NED). Breast Cancer Res Treat. 1999; 53: 105–112.
  • 45
    Dunst J, Steil B, Furch S, et al. Prognostic significance of local recurrence in breast cancer after postmastectomy radiotherapy. Strahlenther Onkol. 2001; 177: 504–510.
  • 46
    Rack B, Janni W, Gerber B, et al. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression? Breast Cancer Res Treat. 2003; 82: 83–92.
  • 47
    Hahnel R, Woodings T, Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979; 44: 671–675.
    Direct Link:
  • 48
    Aamdal S, Bormer O, Jorgensen O, et al. Estrogen receptors and long term prognosis in breast cancer. Cancer. 1984; 53: 2525–2529.
    Direct Link:
  • 49
    Hilsenbeck SG, Ravdin P, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52: 227–237.
  • 50
    Gebauer G, Fehm T, Lang N, Jager W. Tumor size, axillary nodal status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery. Breast Cancer Res Treat. 2002; 75: 167–173.
  • 51
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998; 351: 1451–1467.
  • 52
    International Breast Cancer Study Group. Available at URL: http://www.ibcsg.org/public/general_pages/trials/open/pub_trials_open.shtml [accessed February 7, 2005].
  • 53
    National Surgical Adjuvant Breast and Bowel Project. Available at URL: http://www.nsabp.pitt.edu/B-37.htm [accessed February 7, 2005].
  • 54
    National Comprehensive Cancer Network. Clinical practice guidelines in oncology, version 1, 2005: breast cancer. Available at URL: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf [accessed February 7, 2005].
  • 55
    Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21: 976–983.
  • 56
    Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 12a.
  • 57
    Jorgensen CW, Gradishar WJ. Chemotherapy guidelines for metastatic breast cancer. In: SingletarySE, RobbGL, HortobagyiGN, editors. Advanced therapy of breast disease, 2nd ed. Hamilton, Ontario: B.C. Decker Inc., 2004: 557–566.
  • 58
    Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist. 2004; 9: 518–527.
View Full Article (HTML) Get PDF (196K)